David S. Battleman - 19 Dec 2022 Form 3 Insider Report for LIPELLA PHARMACEUTICALS INC (LIPO)

Role: Director
Signature: /s/ David S. Battleman
Issuer symbol: LIPO
Transactions as of: 19 Dec 2022
Net transactions value: $0
Form type: 3
Filing time: 03 Jan 2023, 16:04:39 UTC
Next filing: 21 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LIPO	Stock Options							19 Dec 2022	Common Stock	40,000	$1.25	Direct	F1
holding	LIPO	Stock Options							19 Dec 2022	Common Stock	10,000	$1.25	Direct	F2
holding	LIPO	Stock Options							19 Dec 2022	Common Stock	10,000	$3.75	Direct	F3
holding	LIPO	Stock Options							19 Dec 2022	Common Stock	10,000	$5.00	Direct	F4
holding	LIPO	Stock Options							19 Dec 2022	Common Stock	34,000	$5.00	Direct	F5
holding	LIPO	Stock Options							19 Dec 2022	Common Stock	10,000	$5.00	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Number of shares of Common Stock beneficially owned consists of 40,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $1.25 per share.
F2	Number of shares of Common Stock beneficially owned consists of 10,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $1.25 per share.
F3	Number of shares of Common Stock beneficially owned consists of 10,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $3.75 per share.
F4	Number of shares of Common Stock beneficially owned consists of 10,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $5.00 per share.
F5	Number of shares of Common Stock beneficially owned consists of 34,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $5.00 per share.
F6	Number of shares of Common Stock beneficially owned consists of 10,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $5.00 per share.